Unassociated Document
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending April 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--

 

 
 
 
 Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc ('Company').
 
On 31 March 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.66 per Ordinary Share, and notional ADSs at a price of $46.80 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2015 to 31 March 2015:
 
 
Non Executive Director
Ordinary Shares
                                                       No. of ADSs
     
Sir Christopher Gent
3,991.060
 
     
Professor Sir Roy Anderson
458.972
 
     
Dr Stephanie Burns
 
486.201
     
Stacey Cartwright
339.240
 
     
Lynn  Elsenhans
 
1,103.464
     
Sir Philip Hampton
339.240
 
     
Judy Lewent
 
539.049
     
Sir Deryck Maughan
 
1,479.741
     
Dr Daniel Podolsky
 
1,109.806
     
Urs Rohner
339.240
 
     
Tom de Swaan
419.061
 
     
Jing Ulrich
 
306.518
     
Hans Wijers
339.240
 
     
The Company and the Non-Executive Directors were informed of these allocations on 1 April 2015.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
V A Whyte
Company Secretary
 
1 April 2015
 

 
 
 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 01, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc